Abstract
Sickle cell anemia and other hemoglobinopathies represent a major health problem in the United States. In April 1987 several federal agencies sponsored a National Institutes of Health Consensus Development Conference to discuss the issues involved in diagnosing and treating some of the major hemoglobinopathies in infants. This report summarizes the consensus panel's answers to the following questions considered by the conference participants: 1) are newborn screening programs for sickle cell anemia effective in reducing morbidity and mortality?, 2) what are the current screening techniques and their efficacies?, 3) what are the risk/benefit considerations in newborn screening programs?, 4) once infants with hemoglobinopathies have been identified, what are the optimal follow-up and management strategies?, and 5) what directions should research follow?
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: JAMA: The Journal of the American Medical Association
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
